TOST - This Toast Analyst Sees Surge In GLP-1 Drugs & More Spoiling Long Term Growth Prospects | Benzinga
Mizuho Securities analyst Dan Dolev downgraded Toast Inc (NYSE: TOST), a digital technology platform built for restaurants, to Neutral from Buy and lowered the price target to $16 from $30.
The analyst is bearish on the company's muted success in enterprise business (as volumes per location slows faster than restaurant inflation), higher reliance on TOST Capital, and potential headwinds from student loan payments leading to declining restaurant spending.
In the long term, Dolev believes that ...